ANAB250117P45000
- 0.00
- 0.000.00%
AnaptysBio Newsroom
Truist Financial Maintains AnaptysBio(ANAB.US) With Hold Rating, Maintains Target Price $20
J.P. Morgan Maintains AnaptysBio(ANAB.US) With Buy Rating, Cuts Target Price to $36
AnaptysBio Price Target Cut to $36.00/Share From $66.00 by JP Morgan
AnaptysBio Is Maintained at Overweight by JP Morgan
Truist Financial Maintains AnaptysBio(ANAB.US) With Hold Rating, Announces Target Price $20
Truist Securities Cuts Price Target on AnaptysBio to $20 From $30, Maintains Hold Rating
Stifel Maintains AnaptysBio(ANAB.US) With Buy Rating, Cuts Target Price to $41
Stifel Nicolaus Sticks to Their Buy Rating for AnaptysBio (ANAB)
Analysts Offer Insights on Healthcare Companies: Keros Therapeutics (KROS), AnaptysBio (ANAB) and US Physical Therapy (USPH)
AnaptysBio Analyst Ratings
Wells Fargo Maintains Overweight on AnaptysBio, Lowers Price Target to $40
AnaptysBio Price Target Cut to $36.00/Share From $90.00 by Guggenheim
Guggenheim Maintains AnaptysBio(ANAB.US) With Buy Rating, Announces Target Price $36
Wells Fargo Maintains AnaptysBio(ANAB.US) With Buy Rating, Cuts Target Price to $40
Buy Rating on AnaptysBio: Strategic Focus on Rosnilimab Amidst Stock Valuation Opportunity
TD Cowen Maintains AnaptysBio(ANAB.US) With Buy Rating, Announces Target Price $32
AnaptysBio (ANAB) Receives a Buy From TD Cowen
AnaptysBio Analyst Ratings
Hold Rating on AnaptysBio Amidst Setbacks in ANB032 and Rosnilimab Efficacy
HC Wainwright Downgrades AnaptysBio to Neutral From Buy, $19 Price Target